Mechanisms of VIP-induced neuroprotection against neonatal excitotoxicity

Annals of the New York Academy of Sciences

Volumn 1070, Issue , 2006, Pages 512-517

  Rangon, Claire Marie ^a   Dicou, Eleni ^b   Goursaud, Stéphanie ^c   Mounien, Lourdes ^d   Jégou, Sylvie ^d   Janet, Thierry ^c   Muller, Jean Marc ^c   Lelièvre, Vincent ^a   Gressens, Pierre ^a,e  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT DE PHARMACOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^c IPBC CNRS UMR 6187 Pôle Biologie Santé   (France)

^d UNIVERSITÉ DE ROUEN   (France)

^e HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

BDNF; PACAP; PHI; PKC; VPAC2

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE 27; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; IBOTENIC ACID; MESSENGER RNA; PEPTIDE HISTIDINE ISOLEUCINE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2; VPAC1 AGONIST; VPAC2 AGONIST;

ALZHEIMER DISEASE; BRAIN DAMAGE; BRAIN DEVELOPMENT; COMPARATIVE STUDY; CONFERENCE PAPER; DRUG MECHANISM; DRUG POTENCY; ENCEPHALOMALACIA; EXCITOTOXICITY; HUMAN; IN SITU HYBRIDIZATION; NEUROPROTECTION; NONHUMAN; WHITE MATTER;

EID: 33746417938     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1317.071     Document Type: Conference Paper

References (12)

1. VAUDRY, D. et al. 2000. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol. Rev. 2: 269-324.
2. GRESSENS, P. et al. 1993. Growth factor function of vasoactive intestinal peptide in whole cultured mouse embryos. Nature 362: 155-158.
3. GRESSENS, P. et al. 1997. Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J. Clin. Invest. 100: 390-397.
4. GRESSENS, P. et al. 1999. Systemic administration of VIP derivatives and neuroprotection of the developing brain against excitotoxic lesions. J. Pharmacol. Exp. Ther. 288: 1207-1213.
5. RANGON, C.M. et al. 2005. VPAC2 receptors mediate VIP-induced neuroprotection against neonatal excitotoxic brain lesions in mice. J. Pharmacol. Exp. Ther. 314: 745-752.
6. EKBLAD, E. et al. 2000. Characterization of intestinal receptors for VIP and PACAP in rat and in PAC1 receptor knockout mouse. Ann. N. Y. Acad. Sci. 921: 137-147.
7. GRESSENS, P. et al. 1998. Regulation of neuroprotective action of vasoactive intestinal peptide in the murine developing brain by protein kinase C and mitogen-activated protein kinase cascades: in vivo and in vitro studies. J. Neurochem. 70: 2574-2584.
8. MILLIGAN, G. 2004. G protein-coupled receptor dimerization: function and ligand pharmacology. Mol. Pharmacol. 66: 1-7.
9. GRINNINGER, C. et al. 2004. A natural variant type II G protein-coupled receptor for vasoactive intestinal peptide with altered function. J. Biol. Chem. 279: 40259-40262.
10. LANGER, I. & P. ROBBERECHT. 2005. Mutations in the carboxy-terminus of the third intracellular loop of the human recombinant VPAC1 receptor impair VIP-stimulated [Ca2+]i increase but not adenylate cyclase stimulation. Cell. Signal. 17: 17-24.
11. HUSSON, I. et al. 2005. BDNF-induced white matter neuroprotection and stage-dependant neuronal survival following a neonatal excitotoxic challenge. Cereb. Cortex 15: 250-261.
12. GARZON, D., G. YU & M. FAHNESTOCK. 2002. A new brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer's disease parietal cortex. J. Neurochem. 82: 1058-1064.